Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2446002 | 0.83 | CA1 (0.54) | ALDH1A1CA1CA2L3MBTL1TSHR | |
| SCHEMBL2446927 | 0.78 | HSD17B10 (0.55) | ALDH1A1CA1CA2L3MBTL1TSHR | |
| SCHEMBL11883810 | 0.78 | PKM (0.41) | ALDH1A1L3MBTL1TP53KMT2APKM | |
| Terephthalic Acid SCHEMBL332989 | 0.78 | TSHR (0.71) | ALDH1A1CA1CA2L3MBTL1TSHR | |
| SCHEMBL6054668 | 0.77 | CA1 (0.56) | ALDH1A1CA1CA2L3MBTL1TSHR | |
| SCHEMBL2447376 | 0.76 | XDH (0.51) | ALDH1A1CA1CA2L3MBTL1TSHR | |
| SCHEMBL2447375 | 0.76 | XDH (0.51) | ALDH1A1CA1CA2L3MBTL1TSHR | |
| SCHEMBL4959168 | 0.75 | CA1 (0.54) | ALDH1A1CA1CA2L3MBTL1TSHR | |
| SCHEMBL9243495 | 0.75 | CA1 (0.59) | ALDH1A1CA1CA2TSHRTP53 | |
| SCHEMBL9149941 | 0.74 | CA1 (0.48) | ALDH1A1CA1CA2L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8096972-B2 | Devices for intraocular drug delivery | JOHNS HOPKINS UNIVERSITY (US) | 2012-01-17 | — | — | US | claimed |
| US-20090155338-A1 | Chronotherapeutic Ocular Delivery System Comprising a Combination of Prostaglandin and a Beta-Blocker for Treating Primary Glaucoma | ASTON UNIVERSITY (GB) | 2009-06-18 | — | — | US | claimed |
| EP-1928407-B1 | CHRONOTHERAPEUTIC OCULAR DELIVERY SYSTEM COMPRISING A COMBINATION OF PROSTAGLANDIN AND A BETA-BLOCKER FOR TREATING PRIMARY GLAUCOMA | UNIV ASTON (GB) | 2009-03-18 | — | — | EP | claimed |
| EP-1928407-A1 | CHRONOTHERAPEUTIC OCULAR DELIVERY SYSTEM COMPRISING A COMBINATION OF PROSTAGLANDIN AND A BETA-BLOCKER FOR TREATING PRIMARY GLAUCOMA | Aston University (GB) | 2008-06-11 | — | — | EP | claimed |
| WO-2007034140-A1 | CHRONOTHERAPEUTIC OCULAR DELIVERY SYSTEM COMPRISING A COMBINATION OF PROSTAGLANDIN AND A BETA-BLOCKER FOR TREATING PRIMARY GLAUCOMA | ASTON UNIVERSITY (GB) | 2007-03-29 | — | — | WO | claimed |
| US-20220409605-A1 | OPHTHALMIC COMPOSITION | Sydnexis, Inc. | 2022-12-29 | — | — | US | disclosed |
| US-20220409603-A1 | OPHTHALMIC COMPOSITION | Sydnexis, Inc. | 2022-12-29 | — | — | US | disclosed |
| US-20220409604-A1 | OPHTHALMIC COMPOSITION | Sydnexis, Inc. | 2022-12-29 | — | — | US | disclosed |
| US-20220378775-A1 | OPHTHALMIC COMPOSITION | Sydnexis, Inc. | 2022-12-01 | — | — | US | disclosed |
| US-20220265632-A1 | OPHTHALMIC COMPOSITION | Sydnexis, Inc. | 2022-08-25 | — | — | US | disclosed |
| US-20220265631-A1 | OPHTHALMIC COMPOSITION | Sydnexis, Inc. | 2022-08-25 | — | — | US | disclosed |
| US-11382909-B2 | Ophthalmic composition | Sydnexis, Inc. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-0707464-A4 | OCULAR INSERT WITH ANCHORING PROTRUSIONS | DAROUGAR SOHRAB (GB) | 1997-03-26 | — | — | EP | disclosed |
| EP-0707464-A1 | OCULAR INSERT WITH ANCHORING PROTRUSIONS | Darougar, Sohrab (GB) | 1996-04-24 | — | — | EP | disclosed |
| US-5466233-A | Tack for intraocular drug delivery and method for inserting and removing same | ESCALON OPHTHALMICS, INC. (US) | 1995-11-14 | — | — | US | disclosed |
| WO-1995028984-A1 | TACK FOR INTRAOCULAR DRUG DELIVERY AND METHOD FOR INSERTING AND REMOVING SAME | ESCALON OPHTHALMICS, INC. (US) | 1995-11-02 | — | — | WO | disclosed |
| US-5395618-A | Controlled sustained release of an ophthalmic drug | ESCALON OPHTHALMICS, INC. (US) | 1995-03-07 | — | — | US | disclosed |
| WO-1995001764-A2 | OCULAR INSERT WITH ANCHORING PROTRUSIONS | DAROUGAR SOHRAB (GB) | 1995-01-19 | — | — | WO | disclosed |
| US-5322691-A | Flexible body; sustained release by diffusion, osmosis or bioerosion | PNC BANK - NATIONAL ASSOCIATION | 1994-06-21 | — | — | US | disclosed |
| US-5147647-A | Drug delivery | PNC BANK - NATIONAL ASSOCIATION | 1992-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409605-A1 | OPHTHALMIC COMPOSITION | MYOC, PDE6H, PDE6C | ALDH1A1 1319/4885CA1 2891/4885CA2 581/4885 |
| US-20220265632-A1 | OPHTHALMIC COMPOSITION | MYOC, PDE6H, PDE6C | ALDH1A1 1319/4885CA1 2891/4885CA2 581/4885 |
| US-20220378775-A1 | OPHTHALMIC COMPOSITION | MYOC, PDE6H, PDE6C | ALDH1A1 1319/4885CA1 2891/4885CA2 581/4885 |
| US-11382909-B2 | Ophthalmic composition | MYOC, PDE6H, PDE6C | ALDH1A1 1319/4885CA1 2891/4885CA2 581/4885 |
| US-20220265631-A1 | OPHTHALMIC COMPOSITION | MYOC, PDE6H, PDE6C | ALDH1A1 1319/4885CA1 2891/4885CA2 581/4885 |
| US-20220409603-A1 | OPHTHALMIC COMPOSITION | MYOC, PDE6H, PDE6C | ALDH1A1 1319/4885CA1 2891/4885CA2 581/4885 |
| US-20220409604-A1 | OPHTHALMIC COMPOSITION | MYOC, PDE6H, PDE6C | ALDH1A1 1319/4885CA1 2891/4885CA2 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.